Unknown

Dataset Information

0

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).


ABSTRACT: To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes.Randomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA(1c) 7-10%) allocated to one of four once-daily subcutaneous dose increase regimens: lixisenatide 2-step (10 ?g for 1 week, 15 ?g for 1 week, and then 20 ?g; n = 120), lixisenatide 1-step (10 ?g for 2 weeks and then 20 ?g; n = 119), placebo 2-step (n = 61), or placebo 1-step (n = 61) (placebo groups were combined for analyses). Primary end point was HbA(1c) change from baseline to week 12.Once-daily lixisenatide significantly improved HbA(1c) (mean baseline 8.0%) in both groups (least squares mean change vs. placebo: -0.54% for 2-step, -0.66% for 1-step; P < 0.0001). Significantly more lixisenatide patients achieved HbA(1c) <7.0% (52.2% 2-step, 46.5% 1-step) and ? 6.5% (31.9% 2-step, 25.4% 1-step) versus placebo (26.8% and 12.5%, respectively; P < 0.01). Lixisenatide led to marked significant improvements of 2-h postprandial glucose levels and blood glucose excursions measured during a standardized breakfast test. A significant decrease in fasting plasma glucose was observed in both lixisenatide groups versus placebo. Mean decreases in body weight (?2 kg) were observed in all groups. The most common adverse events were gastrointestinal-nausea was the most frequent (lixisenatide 23% overall, placebo 4.1%). Symptomatic hypoglycemia occurred in 1.7% of lixisenatide and 1.6% of placebo patients, with no severe episodes. Safety/tolerability was similar for the two dose regimens.Once-daily lixisenatide monotherapy significantly improved glycemic control with a pronounced postprandial effect (75% reduction in glucose excursion) and was safe and well tolerated in type 2 diabetes.

SUBMITTER: Fonseca VA 

PROVIDER: S-EPMC3357248 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).

Fonseca Vivian A VA   Alvarado-Ruiz Ricardo R   Raccah Denis D   Boka Gabor G   Miossec Patrick P   Gerich John E JE  

Diabetes care 20120319 6


<h4>Objective</h4>To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes.<h4>Research design and methods</h4>Randomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA(1c) 7-10%) allocated to one of four once-daily subcutaneous dose increase regimens: lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, and then 20 μg; n = 120), lixisenatide 1-step (10 μg for 2 weeks and then 20 μg; n = 119), placebo 2-step (n = 61), or placebo 1-step (  ...[more]

Similar Datasets

| S-EPMC3747925 | biostudies-literature
| S-EPMC3747937 | biostudies-literature
| S-EPMC4269639 | biostudies-literature
| S-EPMC3747901 | biostudies-literature
| S-EPMC3781502 | biostudies-literature
| S-EPMC3752965 | biostudies-literature
2023-07-05 | GSE236333 | GEO
| S-EPMC8692181 | biostudies-literature
| S-EPMC5299604 | biostudies-literature
| S-EPMC5813234 | biostudies-literature